
Keywords: BTZ; bortezomib; CFZ; carfilzomib; C-L; caspase-like; CNS; central nervous system; CT-L; chymotrypsin-like; CYPs; cytochrome P450 enzymes; iP; immunoproteasome; IXZ; ixazomib; MM; multiple myeloma; OPZ; oprozomib; PD; pharmacodynamic; PI; proteasome inhib